Title: A gene expression map of host immune response in human brucellosis

2

Authors: Ioannis Mitroulis^{1,2}, Akrivi Chrysanthopoulou¹, Georgios Divolis³,
Charalampos Ioannidis⁴, Maria Ntinopoulou¹, Athanasios Tasis¹, Theocharis
Konstantinidis^{1,5}, Natalia Soteriou⁶, George Lallas⁶, Stella Mitka⁷, Mathias Lesche⁸,
Andreas Dahl⁸, Stephanie Gembardt⁴, Maria Panopoulou⁵, Paschalis Sideras³, Ben
Wielockx⁴, Ünal Coskun⁴, Konstantinos Ritis^{1,2}, Panagiotis Skendros^{1,2*}

8

Affiliations: ¹Laboratory of Molecular Hematology, Democritus University of
Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece, ²First
Department of Internal Medicine, Democritus University of Thrace, University
Hospital of Alexandroupolis, Alexandroupolis, Greece; ³Biomedical Research
Foundation Academy of Athens, Center for Clinical, Experimental Surgery and
Translational Research, Athens, Greece; ⁴Institute for Clinical Chemistry and
Laboratory Medicine, Faculty of Medicine, Technische Universität Dresden, 01307
Dresden, Germany; ⁵Laboratory of Microbiology, Democritus University of Thrace,
University Hospital of Alexandroupolis, Alexandroupolis, Greece; ⁶P. Zafiropoulos
SA, Athens, Greece; ⁷School of Biomedical Sciences, International Hellenic
University, Thessaloniki, Greece; ⁸DRESDEN-concept Genome Center, c/o Center
for Molecular and Cellular Bioengineering, Technische Universität Dresden, Dresden,
Germany

22

***Correspondence:**

Panagiotis Skendros, MD, PhD, University Hospital of Alexandroupolis, Dragana,
Alexandroupolis 68100, Greece. E-mail: pskendro@med.duth.gr

26 ABSTRACT

27 Brucellosis is a common zoonotic disease caused by intracellular pathogens of the
 28 genus *Brucella*. *Brucella* infects macrophages and evades clearance mechanisms,
 29 which results in chronic parasitism. Herein, we studied the molecular changes that
 30 take place in human brucellosis both *in vitro* and *in vivo*. RNA sequencing was
 31 performed in primary human macrophages (Mφ) and polymorphonuclear neutrophils
 32 (PMNs) infected with clinical strains of *B. melitensis*. We observed a downregulation
 33 in the expression of genes involved in host response, such as TNF signaling, IL-1β
 34 production and phagosome formation in Mφ, and phosphatidylinositol signaling and
 35 TNF signaling in PMNs, being in line with the ability of the pathogen to survive
 36 within phagocytes. Further transcriptomic analysis of isolated peripheral blood
 37 mononuclear cells (PBMCs) and PMNs from patients with acute brucellosis before
 38 treatment initiation and after successful treatment revealed a positive correlation of
 39 the molecular signature of active disease with pathways associated with response to
 40 interferons (IFN). We identified 24 common genes that were significantly altered in
 41 both PMNs and PBMCs, including genes involved in IFN signaling that were
 42 downregulated after treatment in both cell populations, and *IL1R1* that was
 43 upregulated. The levels of several inflammatory mediators were evaluated in the
 44 serum of these patients, and we observed increased levels of IFN-γ, IL-1β and IL-6
 45 before the treatment of acute brucellosis. An independent cohort of patients with
 46 chronic brucellosis also revealed the increased levels of IFN-γ during relapse
 47 compared to remissions. Taken together, this study provides for the first time an in-
 48 depth analysis of the molecular alterations that take place in human phagocytes upon
 49 infection, and in peripheral blood immune populations during active disease.

50 **Keywords**

51 Brucellosis; immunity; transcriptomics; macrophages; polymorphonuclear

52 neutrophils; peripheral blood mononuclear cells

53 INTRODUCTION

54 Brucellosis is a common bacterial zoonotic disease worldwide and an emerging
55 zoonosis in several developed countries (1,2). Despite its importance in public health
56 remains widespread and neglected in many areas, including southeastern Europe,
57 Asia, Central and Latin America, and Africa (2,3). It is caused by intracellular
58 pathogens of the genus *Brucella* that have domestic animals, mainly goats, sheep and
59 cows, as natural reservoirs. The disease is transmitted to humans by consumption of
60 unpasteurized milk and dairy products or by occupational contact with infected
61 animals (4). Additionally, *Brucella* is highly infectious through the aerosol route, thus
62 is considered as one of the most common laboratory-acquired pathogens and is also
63 classified as a category B agent on the biodefense list (5,6).

64 Human brucellosis causes high morbidity and protean clinical manifestations,
65 mimicking many infectious and non-infectious diseases since it can affect multiple
66 organs. Despite early diagnosis and prolonged therapy with antibiotics is associated
67 with substantial residual disability (4,7). Up to 30% of patients develop chronic
68 disease, which is characterized by atypical clinical manifestations, high frequency of
69 focal complications such as spondylitis, chronic fatigue syndrome, and relapses (7,8).

70 Host protection against *Brucella* and prevention of its intracellular parasitism in
71 macrophages depends on cell-mediated immunity, involving adequate Th1 immune
72 response, with significant production of interferon gamma (IFN- γ) (8). Recent data
73 support also an emerging key role of innate immunity and neutrophils in early
74 proinflammatory responses against *Brucella* that may affect T-cell dynamics during
75 infection (9,10). On the other hand, *Brucella* has developed various stealthy strategies
76 to evade innate and adaptive immune responses, in order to establish intracellular
77 long-term survival and replication (9,11). Several studies have demonstrated that

78 patients with chronic brucellosis display defective cell-mediated immunity
 79 (brucellosis-acquired cellular anergy) probably due to modulation of host cellular
 80 immunity by Brucella (12). However, immunopathogenesis of human brucellosis
 81 remains incompletely understood and integrated molecular data that characterize
 82 complex interactions between Brucella and host immunity are missing today.
 83 Here, we provide a gene expression map that guides the molecular signature of
 84 macrophages (M ϕ) and polymorphonuclear neutrophils (PMNs) during the crucial
 85 early events of Brucella infection. Moreover, we analyse the transcriptomic alterations
 86 that take place concomitantly in peripheral blood mononuclear cells (PBMCs) and
 87 PMNs of patients upon treatment uncovering candidate molecular targets and
 88 pathways that may characterize active infection and disease eradication.

89 MATERIALS AND METHODS

90 Patients

91 Ten adult patients with acute brucellosis were recruited. EDTA anticoagulated blood
 92 and serum were collected from patients with active brucellosis before the initiation of
 93 antibiotic treatment and three months after the completion of treatment, when all
 94 patients were successfully treated. The diagnosis was based on compatible clinical
 95 manifestations in combination with high serum titers of anti-brucellar antibodies
 96 (Wright's agglutination test ≥ 160) or a four-fold increase of the initial titers in two-
 97 paired samples drawn 2 weeks apart, or/and Brucella isolation. None of these patients
 98 suffered any relapse during a six-month post-treatment follow-up period. Patient
 99 characteristics and treatment are described in Table 1. PBMCs and PMNs were
 100 simultaneously isolated. RNA was isolated using TRIzol reagent (ThermoScientific).
 101 Sera from a second cohort of 25 chronic relapsing brucellosis patients at clinical
 102 relapse and remission, were also used. These patients had a disease duration of ≥ 12
 103 months in combination with positive serum agglutination tests (SATs) or/and
 104 complement fixation test, or/and Brucella isolation (Supplementary Table 1).
 105 Exclusion criteria were co-existence of other infectious, neoplastic or autoimmune
 106 disease, administration of immunomodulating agents or vaccination for at least 4
 107 weeks before the entry to study, and pregnancy. The study was approved by the Local
 108 Scientific and Ethics Committee of the University Hospital of Alexandroupolis,
 109 Greece. All subjects provided written informed consent in accordance with the
 110 principles expressed in the Declaration of Helsinki.

111 M ϕ differentiation

112 Human M ϕ were differentiated from isolated PBMCs from four control subjects, as
 113 previously described with modifications (13). In brief, PBMCs were isolated from

114 healthy donors by density gradient centrifugation, using Histopaque 1077 (Sigma). To
115 promote M ϕ differentiation, monocytes were isolated using plastic adherence and
116 cells were cultured in the presence of 10% autologous serum for 6 days.

117 ***In vitro* infection**

118 Clinical strains of *B. melitensis* were used for *in vitro* experiments. Bacterial inoculum
119 for cell infection was cultured on blood agar for 3 days. Bacterial suspension with 0.5
120 McFarland was opsonized for 30 minutes using human serum and then diluted in
121 RPMI and $\sim 10^7$ bacteria in 0.5 ml of RPMI were added to each well (20 MOI) of
122 PMNs or M ϕ . Subsequently, cells were cultured for 0.5h for PMNs and 2h and 24h
123 for M ϕ , washed twice and RNA was isolated, using TRIzol reagent
124 (ThermoScientific). Untreated PMNs and untreated M ϕ , cultured for 2h served as
125 control, respectively. The experimental procedure with *B. melitensis* was performed at
126 biosafety level 3.

127 **RNA sequencing**

128 RNA sequencing for M ϕ and PBMCs was performed as previously described (14). To
129 analyze RNA sequencing data, fragments were aligned with GSNAP (2020-12-16) to
130 the human reference (hg38), and Ensembl annotation version 98 was used for the
131 splice site support. Uniquely aligned fragments were counted with featureCounts
132 (subread v2.0.1), again with the support of the Ensembl annotation. The exploratory
133 analysis was performed with the DESeq 2 (v1.24.0) package within R (v3.6.3). Bias
134 for patients was assessed using an exploratory correction with the variance stabilized
135 transformation data of DESeq2 and the removeBatchEffect function of edgeR
136 (3.26.8). Differential expression between before and after treatment was performed
137 with a correction for patient.

For PMNs, 1000 ng of total RNA were used for the preparation of cDNA libraries, using the TruSeq RNA Library Preparation Kit v2 (Illumina), according to the manufacturer's instructions. Library quality was evaluated using the Agilent DNA 1000 Kit (Agilent) with an Agilent 2100 Bioanalyzer. Quantification was performed by amplifying a set of six pre-diluted DNA standards (KAPA Biosystems) and diluted cDNA libraries by RT-qPCR. Isomolar quantities of up to 20 cDNA libraries, barcoded with different adaptors, were multiplexed. Sequencing was performed in a single-end manner at the Greek Genome Center, using a NextSeq 500/550 75c kit (Illumina) for the in vitro samples and a NovaSeq 6000 SP 100c kit (Illumina) for the ex vivo samples, generating 75 bp and 100 bp long reads, respectively, and an average of 25 million reads per library. Raw sequence data in FastQ format were uploaded to the Galaxy web platform, and standard tools of the public server "usegalaxy.org" were used for subsequent analysis (15). Briefly, quality control of raw reads was performed with FastQC (v0.72+galaxy1), followed by removal of adapter sequences and low-quality bases using Trim Galore! (v0.6.3). Next, HISAT2 (v2.2.1+galaxy0) was applied for the alignment of trimmed reads to the Homo sapiens (human) genome assembly GRCh37 (hg19) from Genome Reference Consortium. Assessment of uniform read coverage for exclusion of 5'/3' bias and evaluation of RNA integrity at the transcript level were performed using Gene Body Coverage (v2.6.4.3) and Transcript Integrity Number (v2.6.4.1) tools, respectively. Differential gene expression was determined with DESeq2 (v2.11.40.6+galaxy1), using the count tables generated from HTSeq-count (v0.9.1) as input. The variability within and between individuals of this paired-data study was incorporated in the analysis, considering the treatment as the primary factor and the individual/patient as the secondary factor affecting gene expression.

163 Pathway and biological processes analysis was performed using the Enrichr analysis
164 tool (14,16). Heat maps were generated using the Morpheus software (Broad
165 Institute). Gene set enrichment (GSEA) pre-ranked analysis (1000 permutations,
166 minimum term size of 15, maximum term size of 500) was performed using the
167 GSEA software (Broad Institute). Gene sets were ranked by taking the -log10
168 transform of the p-value and signed as positive or negative based on the direction of
169 fold change. Annotated gene sets from Molecular Signatures Database (MSigDB)
170 were used as input (16).

171 **Cytokine measurement**

172 The levels of cytokines were measured using the LEGENDplex™ Multi-Analyte
173 Flow Assay Kit (Biolegend) in a CyFlow Cube 8 flow cytometer (Sysmex Partec,
174 Germany), according to manufacturer's instructions. For comparisons between the
175 groups the Wilcoxon signed-rank test for paired samples was used. Statistical analysis
176 was performed using GraphPad Prism (GraphPad Inc., La Jolla, CA). Significance
177 was set at $p < 0.05$.

178 RESULTS

179 Analysis of the molecular signature of human macrophages infected *in vitro* with 180 *B. melitensis*

181 To provide a time-course analysis of the molecular alterations of human M ϕ during
182 infection with *B. melitensis*, we performed *in vitro* infection of human M ϕ , derived
183 from the differentiation of peripheral blood monocytes from control subjects, and
184 compared the transcriptomic signature of untreated M ϕ compared to that of infected
185 cells at 2h and 24h post-infection. Principal component analysis (PCA) revealed that
186 there was a prominent change in the transcriptomic profile of M ϕ at 24h after
187 infection compared to untreated cells and cells at 2h after infection (Figure 1A).
188 Pathway analysis, using the Kyoto Encyclopedia of Genes and Genomes (KEGG)
189 database, of the significantly upregulated differentially expressed genes (DEG) (False
190 Discovery Rate/FDR <0.01) between untreated M ϕ and M ϕ at 2h post-infection
191 revealed an overrepresentation of circadian rhythm and ribosome biogenesis
192 pathways, whereas downregulated DEGs were enriched in pathways associated with
193 viral infection and infection from intracellular pathogens processes, including herpes
194 simplex virus 1 infection, hepatitis C, and salmonella infection and TNF signaling
195 (Figure 1B, C). Interestingly, we observed a decreased expression of genes encoding
196 proteins critical in pathogen recognition, such as *NOD1*, *TLR5*, *TLR6* and *NLRC4*
197 (Figure 1C).

198 We next assessed the molecular changes that take place at 24h post-infection. Pathway
199 analysis of the downregulated DEGs with the highest variance (log2 fold change > 2
200 and < -2, FDR<0.01) showed overrepresentation of pathways associated with
201 infection with *Staphylococcus aureus* and infection with intracellular pathogens, such
202 as leishmaniasis and tuberculosis, as well as the pathways associated with phagosome

203 and lysosome (Figure 1D). No statistically significant pathway was observed at the
 204 respective analysis of upregulated genes. Further, analysis of the DEGs that were
 205 downregulated at 24h after infection revealed that they are involved in biological
 206 processes associated with inflammation, and more specifically with the production of
 207 IL-1 and M ϕ function (Figure 1E). Regarding the genes involved in the
 208 aforementioned pathways, there was a downregulation of several genes involved in
 209 the phagosome formation and function at 24h after infection, including those
 210 encoding for several Fc γ receptors (*FCGR1A*, *FCGR2A*, *FCGR2B*, *FCGR2C*,
 211 *FCGR3A*, *FCGR3B*), toll-like receptors (*TLR2*, *TLR4*, *TLR6*), other sensors of
 212 pathogen-associated molecular patterns (*CLEC7A*, *CD14*), integrins and other
 213 receptors involved in phagocytosis (*ITGB3*, *ITGAM*, *ITGB2*, *CD36*) (Figure 3D). We
 214 also observed a downregulation in the expression of genes encoding cytokines and
 215 cytokine receptors of the IL-1 family (*IL18*, *IL1RN*, *IL36RN*), chemokines (*CCL1*,
 216 *CCL2*, *CCL7*, *CCL8*, *CCL13*, *CXCL9*) and chemokine receptors (*CCR1*, *CCR2*,
 217 *CCR3*, *CCR5*), formyl peptide receptors (*FPR1*, *FPR2*, *FPR3*), and complement
 218 anaphylatoxin receptors (*C3AR1*, *C5AR1*, *C5AR2*) (Figure 1F). Regarding the
 219 regulation of IL-1 production, we observed the downregulation of several genes
 220 encoding inflammasome sensors (*NLRC4*, *NLRP12*, *MEFV*, *AIM2*), the adaptor
 221 *PYCARD*, and the gene that encodes the effector *CASP1* (Figure 1F). Taken together,
 222 infection of M ϕ with *B. melitensis* drives major changes in the transcriptomic profile
 223 of infected M ϕ , downregulating a plethora of genes involved in the formation of
 224 phagosomes and the recognition of pathogens, in an effort to preserve pathogen
 225 survival within M ϕ .
 226

227 Analysis of the molecular signature of human PMNs infected *in vitro* with *B.* 228 *melitensis*

229 Even though Mφ are the major cell population infected by *Brucella* spp, it has been
230 previously shown that this pathogen can also infect neutrophils (17). In order to
231 characterize the molecular signature of infected PMNs with *B. melitensis*, we
232 performed *in vitro* infection of human PMNs for 0.5h, derived from control subjects,
233 and compared the transcriptomic signature of untreated PMNs to that of infected cells.
234 Pathway analysis of the significantly overexpressed DEGs (FDR<0.01), using the
235 KEGG database, highlighted Ribosome as the top upregulated pathway in *Brucella*-
236 infected PMNs (Figure 2A). Notably, almost all genes (75 out of the 79) encoding for
237 structural proteins of both small and large subunits of cytoplasmic ribosomes were
238 found significantly upregulated (Figure 2B). Respective analysis of the downregulated
239 DEGs demonstrated modulation of several pathways, some of which were also
240 downregulated in *Brucella*-infected Mφ at 2h post-infection, such as TNF signaling
241 and herpes simplex virus 1 infection (Figures 1B and 2C). However, various
242 inflammation-related biological processes were significantly downregulated
243 selectively in PMNs, namely the phosphatidylinositol signaling, NF-kappa B
244 signaling, and cellular senescence pathways (Figure 2B, C). Amongst the
245 downregulated transcripts in *Brucella*-infected PMNs, we identified several
246 modulators of apoptosis (*BIRC3*, *FOXO3*, *DNM1L*, *ITPR1*, *TRAF1*, *TRAF5*) and
247 inflammation, as exemplified by decreased mRNA expression of cytokines and
248 corresponding receptors of the IL-1 family (*IL1A*, *IL1B*, *IL18R1*), chemokines (eg.
249 *CCL20*), and various signaling mediators, such as kinases (*AKT3*, *ATM*, *ATR*, *CDK6*,
250 *DGKD*, *DGKE*, *IPMK*, *IPPK*, *MAPK13*, *MAPK14*, *RPK1*) (Figure 2C).

251

252 Transcriptomic profiling of active human brucellosis

253 We further investigated the transcriptomic signature of active human brucellosis. To
 254 do so, PMNs were isolated from eight patients with active brucellosis before the
 255 initiation of antibiotic treatment (active disease) and three months after completion of
 256 the antibiotic treatment, when patients were free of symptoms (remission).
 257 Transcriptomic analysis identified 318 DEGs (FDR<0.1) (Figure 3A). DEGs that
 258 were upregulated after treatment are involved in RNA transport and autophagy
 259 pathways, whereas downregulated DEGs after treatment are involved in NOD-like
 260 receptor signaling pathway and cytokine-cytokine receptor interaction pathways, as
 261 well as several pathways associated with infectious diseases (Figure 3A). The
 262 upregulated genes that encode proteins involved in RNA transport were the members
 263 of the eukaryotic initiator factors (EIF) family *EIF1*, *EIF3I*, *EIF4A3*, *EIF5*, and the
 264 genes of the autophagy pathway were *ATG2A*, *GABARAPL1*, *TP53INP2*, *DDIT4* and
 265 *IRS2* (Figure 3B). On the other hand, we observed a downregulation of critical genes
 266 in immune regulation, such as *IL1B*, *CX3CR1*, *CCR2*, *CCR5*, *CXCR6*, *STAT1*, *AIM2*,
 267 and *CD40*, as well as genes associated with interferon signaling, such as *OAS1*, *OAS2*,
 268 *GBP1* and *GPB3* (Figure 3B). We further performed gene set enrichment analysis
 269 (GSEA) using the Hallmark Gene Set collection of the Molecular Signatures
 270 Database. We observed a positive correlation of the transcriptomic signature of PMNs
 271 during active brucellosis with IFN- γ and IFN- α response and with inflammatory
 272 response (Figure 3).

273 In parallel, we performed transcriptomic analysis of PBMCs isolated from six patients
 274 with active brucellosis before and after antibiotic treatment. Transcriptomic analysis
 275 identified 62 genes with significantly altered expression (FDR<0.1) after treatment
 276 (Figure 4A). We observed that successful treatment resulted in the increased

expression of *HIF1A*, a critical regulator of inflammation, and of the genes that encode IL-1 receptor *IL1R1*, and its accessory protein *IL1RAP*, which form a complex that mediates IL-1 signal transduction (Figure 4A). On the other hand, there was a downregulation in the expression of genes that play a major role in immune function, such as *CD274*, which encodes PD-L1, *STAT1*, *CD3G*, the intracellular immunoglobulin receptor *TRIM21*, *CXCR6*, the lymphocytic activation molecules *SLMF6*, *SLAMF7* and genes that encode proteins important in effector cell cytolytic processes, such as *CD160*, *GZMA*, *GZMH* (Figure 4A). Moreover, several identified genes are involved in interferon-related activation pathways, such as *GPB3*, *GPB4*, *OAS1*, *OAS2*, *OASL*, *IFIH6*, and *XAF1* (Figure 4A). To the same line, GSEA analysis revealed that the gene sets with the most significant positive association with active disease were IFN signaling and OXPHOS, whereas the one with the most significant negative association was the hypoxia gene set (Figure 4B). Notably, we further identified 24 genes that were differentially expressed both in PMNs and PBMCs (Figure 4C). Among these common genes, *CXCR6*, *TRIM21*, *SLAM7*, *CD274* and the genes associated with IFN signaling *OASL*, *OAS1*, *OAS2*, *GBP3*, and *STAT1* were downregulated in both datasets, whereas *IL1R1* was commonly upregulated (Figure 4D).

295 Cytokine levels in acute brucellosis

To this point, we observed that the molecular signature that characterizes acute brucellosis is positively correlated with those of IFN- α and IFN- γ response. For this reason, we measured the levels of several cytokines in the sera of patients during acute brucellosis and after successful treatment. We observed a significant downregulation in the levels of IFN- γ , IL-1 β and IL-6 post-treatment, whereas there was no statistically significant difference in the levels of IFN- α , IL-18, TNF, MCP-1

302 and IL-17A (Figure 5A-H). We further confirmed that the levels of IFN- γ are
303 increased in active disease in a cohort of patients with chronic relapsing brucellosis.
304 In this cohort, the levels of IFN- γ were increased during relapse compared to
305 remission (Figure 5I).

306 DISCUSSION

307 The interaction between Brucella and host immune system is critical for the
308 development of persistent infection or infection clearance (8,18). To date,
309 transcriptomic data derived from Brucella-infected mouse macrophages or mouse cell
310 lines, domestic ruminants or Brucella-vaccinated animals (19–25). This study
311 analyses, for the first time, the transcriptome profile, both *in vitro*, in Brucella-
312 infected primary Mφ and PMNs, and *ex-vivo*, in PBMCs and PMNs derived from
313 patients with acute brucellosis before and after treatment. This provides the molecular
314 signature that characterizes the main host cellular immune populations during their
315 initial interplay with invading Brucella, and the molecular signature of different stages
316 of the disease.

317 Early molecular events following phagocytosis of Brucella by macrophages are
318 crucial for the activation of innate immunity leading to the induction of a favorable
319 Th1 response (8,18). Several lines of evidence indicated that Brucella manipulates
320 multiple effector mechanisms in macrophages to its own benefit (9,12). In line with
321 this, we identified that in Mφ infected *in vitro* by a clinical strain of *B. melitensis*, the
322 expression of several genes encoding key proteins involved in the recognition of
323 Brucella and in the proinflammatory response against the pathogen were markedly
324 suppressed. These alterations may initiate as soon as 2h post-infection being more
325 prominent at 24h post infection. Interestingly, most downregulated DEGs related to
326 phagosome, TNFα signaling and IL-1β production. Indeed, previous studies reported
327 that various Brucella virulence factors and pathogen-associated molecular patterns
328 (PAMPs), such as Type IV secretory system (T4SS), lipopolysaccharide (LPS) and
329 outer membrane lipoproteins (OMPs) modify phagosome biogenesis and trafficking
330 in macrophages to inhibit phagolysosome fusion, and develop suitable vacuolar

compartments to enable intracellular replication of the microbe (9,12). Moreover, the current study comes in agreement with previous data demonstrated that *Brucella* Omp25 protein inhibits *in vitro* the production of TNF in human Mφ and dendritic cells preventing cell maturation and antigen presentation (26–28). Furthermore, several genes encoding members of the IL-1 family (*IL18*, *IL1RN*, *IL36RN*) and inflammasome complexes (*NLRC4*, *NLRP12*, *MEFV*, *AIM2*, *PYCARD*, *CASP1*) are significantly downregulated in *Brucella*-infected Mφ. Experimental studies indicated that inflammasomes and their effectors are essential for an initial effective immune response against *Brucella* infection (29–31). On the other hand, *Brucella* can regulate canonical and non-canonical inflammasome signaling and pyroptosis in macrophages by impairing caspase-1 and caspase-4/11 activation, and IL-1β secretion (32,33). It is intriguing that *Brucella* downregulates macrophage *MEFV* expression, the gene responsible for familial Mediterranean fever, the prototype IL-1β-mediated autoinflammatory disease (34). Mutations in the *MEFV* gene are highly prevalent in the Middle East and Mediterranean countries where brucellosis is endemic (35). Our data further support the hypothesis that *MEFV* mutations may provide an evolutionary selective advantage to confer protection against brucellosis (36).

Recently, PMNs emerge as novel players during the initial stages of innate immune response against *Brucella* infection (10). *Brucella* resists the killing mechanisms of human PMNs and induces the early death of these cells promoting their phagocytosis by Mφ, which become vehicles for bacterial dispersion within the host (37). Studies in murine brucellosis proposed that infected PMNs attenuate cellular adaptive immunity, given that depletion of PMNs favored bacterial elimination (17,38). Based on these, this study examined the early transcriptome alterations of *in vitro* *Brucella*-infected neutrophils, before their premature death. *B. melitensis*-infected PMNs were

356 characterized by increased expression of genes associated with ribosome biogenesis
357 indicating bulk induction of protein synthesis, in an effort to arm their bactericidal
358 mechanisms and survive. Of interest and in a similar way to Mφ, *in vitro* infection of
359 PMNs with Brucella led to downregulated gene expression in key molecular pathways
360 for PMNs physiology and function including phosphatidylinositol signaling, TNF
361 signaling, and cellular senescence. Phosphatidylinositol signaling pathway plays an
362 important role in membrane dynamics and trafficking, including proteins implicated
363 in endosomal membranes and autophagosome assembly and activity (39,40).
364 Autophagy is closely related to the intracellular lifestyle of many pathogens, including
365 Brucella (41,42). We hypothesize that the downregulation of several autophagy
366 sensors and regulators belonging to phosphatidylinositol pathway further modulates
367 the autophagic capacity of PMNs against Brucella. This may also explain the inability
368 of Brucella-infected PMNs to form neutrophil extracellular traps (NETs) (17), an
369 effector mechanism positively associated with the autophagy machinery (43).
370 Downregulation of the cellular senescent pathway is in agreement with the reported
371 premature death of Brucella-infected PMNs (17). Additionally, senescence has been
372 associated with resistance to cellular death (44). Moreover, it appears that perturbation
373 of TNF signaling represents a common stealth strategy of Brucella to avoid both Mφ-
374 and PMNs-induced inflammation further restricting cellular immunity (11).

375 In order to investigate the impact of human brucellosis in host immunity and identify
376 possible candidate markers of active disease and response to treatment, we next
377 assessed the transcriptome profiling of PBMCs and PMNs isolated from newly
378 diagnosed patients with acute brucellosis, before and three months after their
379 successful treatment. We observed, both in PBMCs and PMNs, transcriptomic
380 alterations related to major pathways of inflammation, supporting its role for infection

381 overcome. PBMCs from patients successfully treated were characterized by the
382 overexpression of genes critically involved in hypoxia (*HIF1A*) and IL-1 signaling,
383 and the downregulation of genes implicated in oxidative phosphorylation, lymphocyte
384 activation, and cytotoxicity. In line with these data, a recent experimental study has
385 demonstrated that absence of HIF-1 α renders mice susceptible to *Brucella* infection,
386 while HIF-1 α reduces oxidative phosphorylation and increases glycolysis leading to
387 inflammasome activation and IL-1 β release in infected macrophages (45).

388 Treatment of brucellosis upregulated in PMNs the expression of several genes related
389 to autophagy machinery, including *DDIT4/REDD1* encoding a key regulator of
390 autophagy-mediated NET formation (47). It seems that after clearance of infection,
391 PMNs restored critical functions impaired by *Brucella*, such as autophagy. However,
392 they did not acquire a proinflammatory phenotype as indicated by the downregulated
393 expression in genes related to pathways that contain NOD-like receptor signaling and
394 cytokine-cytokine interactions.

395 Of note, this study identified a common set of 24 genes that were differentially
396 expressed both in PMNs and PBMCs suggesting candidate molecular
397 diagnostic/prognostic targets for human brucellosis. Among them, IFN pathway,
398 which is the major driver of Th1 immunity against *Brucella* (8), appears to be induced
399 in active disease and attenuated after treatment. Indeed, using patients' sera, we
400 confirm at the protein level, that IFN- γ and other Th1 cytokines, such as IL-1 β and
401 IL-6, were increased during active disease and significantly diminished in cured, non-
402 relapsed patients. Collectively, these results confirmed past studies highlighting the
403 significant role of a robust Th1 response to tackle acute infection and brucellosis-
404 acquired cellular anergy of chronic disease (47–50).

405 In conclusion, this study provides an integrated transcriptome landscape of immune
406 cells signature in human brucellosis suggesting candidate molecular pathways and
407 targets for active disease and response to treatment. Based on these data, future
408 validation and mechanistic studies may further decipher the pathogenesis of this
409 ancient and continuously re-emerging zoonotic disease (1,2,51).

410 **Acknowledgements**

411 This study was supported by the German Federal Ministry for Education and
412 Research (BMBF) and Greek General Secretariat for Research and Technology
413 (GSRT), German-Greek Bilateral Research & Innovation Programme BRIDGING,
414 grant MIS 5030062, and partially was supported by the GSRT, Research & Innovation
415 Programme CYTONET, grant MIS 5048548.

416 References

1. Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. *PLoS Negl Trop Dis*. 2012;6(10):e1865.
2. European Food Safety Authority and European Centre for Disease Prevention and Control (EFSA and ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017. *EFSA J*. 2018 Dec;16(12):e05500.
3. Franc KA, Krecek RC, Häsler BN, Arenas-Gamboa AM. Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action. *BMC Public Health*. 2018 Jan 11;18(1):125.
4. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. *N Engl J Med*. 2005 Jun 2;352(22):2325–36.
5. Pereira CR, Cotrim de Almeida JVF, Cardoso de Oliveira IR, Faria de Oliveira L, Pereira LJ, Zangerônimo MG, et al. Occupational exposure to *Brucella* spp.: A systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2020 May;14(5):e0008164.
6. Pappas G, Panagopoulou P, Christou L, Akritidis N. *Brucella* as a biological weapon. *Cell Mol Life Sci*. 2006 Oct;63(19–20):2229–36.
7. Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2012;6(12):e1929.
8. Skendros P, Pappas G, Boura P. Cell-mediated immunity in human brucellosis. *Microbes Infect*. 2011 Feb;13(2):134–42.
9. Jiao H, Zhou Z, Li B, Xiao Y, Li M, Zeng H, et al. The Mechanism of Facultative Intracellular Parasitism of *Brucella*. *Int J Mol Sci*. 2021 Apr 1;22(7):3673.
10. Moreno E, Barquero-Calvo E. The Role of Neutrophils in Brucellosis. *Microbiol Mol Biol Rev*. 2020 Nov 18;84(4):e00048-20.
11. Martirosyan A, Moreno E, Gorvel J-P. An evolutionary strategy for a stealthy intracellular *Brucella* pathogen. *Immunol Rev*. 2011 Mar;240(1):211–34.
12. Skendros P, Boura P. Immunity to brucellosis. *Rev Sci Tech*. 2013 Apr;32(1):137–47.
13. Kourtzelis I, Li X, Mitroulis I, Grosser D, Kajikawa T, Wang B, et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. *Nat Immunol*. 2019 Jan;20(1):40–9.
14. Mitroulis I, Ruppova K, Wang B, Chen L-S, Grzybek M, Grinenko T, et al. Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity. *Cell*. 2018 Jan 11;172(1–2):147–161.e12.

15. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res.* 2018 Jul 2;46(W1):W537–44.
16. Lamprianidou E, Kordella C, Kazachenka A, Zoulia E, Bernard E, Filia A, et al. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine. *Blood Adv.* 2021 Jan 12;5(1):129–42.
17. Barquero-Calvo E, Martirosyan A, Ordoñez-Rueda D, Arce-Gorvel V, Alfaro-Alarcón A, Lepidi H, et al. Neutrophils exert a suppressive effect on Th1 responses to intracellular pathogen *Brucella abortus*. *PLoS Pathog.* 2013 Feb;9(2):e1003167.
18. de Figueiredo P, Ficht TA, Rice-Ficht A, Rossetti CA, Adams LG. Pathogenesis and immunobiology of brucellosis: review of *Brucella*-host interactions. *Am J Pathol.* 2015 Jun;185(6):1505–17.
19. Zhou Z, Gu G, Luo Y, Li W, Li B, Zhao Y, et al. Immunological pathways of macrophage response to *Brucella ovis* infection. *Innate Immun.* 2020 Oct;26(7):635–48.
20. Zhou D, Zhi F, Fang J, Zheng W, Li J, Zhang G, et al. RNA-Seq Analysis Reveals the Role of Omp16 in *Brucella*-Infected RAW264.7 Cells. *Front Vet Sci.* 2021;8:646839.
21. Solanki KS, Gandham RK, Thomas P, Chaudhuri P. Transcriptome analysis of *Brucella abortus* S19Δper immunized mouse spleen revealed activation of MHC-I and MHC-II pathways. *Access Microbiol.* 2020;2(1):acmi000082.
22. Hop HT, Arayan LT, Reyes AWB, Huy TXN, Min W, Lee HJ, et al. Simultaneous RNA-seq based transcriptional profiling of intracellular *Brucella abortus* and *B. abortus*-infected murine macrophages. *Microb Pathog.* 2017 Dec;113:57–67.
23. Liu Q, Han W, Sun C, Zhou L, Ma L, Lei L, et al. Deep sequencing-based expression transcriptional profiling changes during *Brucella* infection. *Microb Pathog.* 2012 Dec;52(5):267–77.
24. Rossetti CA, Galindo CL, Everts RE, Lewin HA, Garner HR, Adams LG. Comparative analysis of the early transcriptome of *Brucella abortus*-infected monocyte-derived macrophages from cattle naturally resistant or susceptible to brucellosis. *Res Vet Sci.* 2011 Aug;91(1):40–51.
25. Wang F, Hu S, Liu W, Qiao Z, Gao Y, Bu Z. Deep-sequencing analysis of the mouse transcriptome response to infection with *Brucella melitensis* strains of differing virulence. *PLoS One.* 2011;6(12):e28485.
26. Jubier-Maurin V, Boigegrain RA, Cloeckert A, Gross A, Alvarez-Martinez MT, Terraza A, et al. Major outer membrane protein Omp25 of *Brucella suis* is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. *Infect Immun.* 2001 Aug;69(8):4823–30.

27. Caron E, Gross A, Liautard JP, Dornand J. Brucella species release a specific, protease-sensitive, inhibitor of TNF- α expression, active on human macrophage-like cells. *J Immunol.* 1996 Apr 15;156(8):2885–93.
28. Billard E, Dornand J, Gross A. Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor α secretion. *Infect Immun.* 2007 Oct;75(10):4980–9.
29. Costa Franco MMS, Marim FM, Alves-Silva J, Cerqueira D, Rungue M, Tavares IP, et al. AIM2 senses Brucella abortus DNA in dendritic cells to induce IL-1 β secretion, pyroptosis and resistance to bacterial infection in mice. *Microbes Infect.* 2019 Mar;21(2):85–93.
30. Lacey CA, Mitchell WJ, Dadelahi AS, Skyberg JA. Caspase-1 and Caspase-11 Mediate Pyroptosis, Inflammation, and Control of Brucella Joint Infection. *Infect Immun.* 2018 Sep;86(9):e00361-18.
31. Gomes MTR, Campos PC, Oliveira FS, Corsetti PP, Bortoluci KR, Cunha LD, et al. Critical role of ASC inflammasomes and bacterial type IV secretion system in caspase-1 activation and host innate resistance to Brucella abortus infection. *J Immunol.* 2013 Apr 1;190(7):3629–38.
32. Jakka P, Namani S, Murugan S, Rai N, Radhakrishnan G. The Brucella effector protein TcpB induces degradation of inflammatory caspases and thereby subverts non-canonical inflammasome activation in macrophages. *J Biol Chem.* 2017 Dec 15;292(50):20613–27.
33. Campos PC, Gomes MTR, Marinho FAV, Guimarães ES, de Moura Lodi Cruz MGF, Oliveira SC. Brucella abortus nitric oxide metabolite regulates inflammasome activation and IL-1 β secretion in murine macrophages. *Eur J Immunol.* 2019 Jul;49(7):1023–37.
34. Skendros P, Papagoras C, Mitroulis I, Ritis K. Autoinflammation: Lessons from the study of familial Mediterranean fever. *J Autoimmun.* 2019 Nov;104:102305.
35. Özen S. Update on the epidemiology and disease outcome of Familial Mediterranean fever. *Best Pract Res Clin Rheumatol.* 2018 Apr;32(2):254–60.
36. Ross JJ. Goats, germs, and fever: Are the pyrin mutations responsible for familial Mediterranean fever protective against Brucellosis? *Med Hypotheses.* 2007;68(3):499–501.
37. Gutiérrez-Jiménez C, Mora-Cartín R, Altamirano-Silva P, Chacón-Díaz C, Chaves-Olarte E, Moreno E, et al. Neutrophils as Trojan Horse Vehicles for Brucella abortus Macrophage Infection. *Front Immunol.* 2019;10:1012.
38. Mora-Cartín R, Gutiérrez-Jiménez C, Alfaro-Alarcón A, Chaves-Olarte E, Chacón-Díaz C, Barquero-Calvo E, et al. Neutrophils Dampen Adaptive Immunity in Brucellosis. *Infect Immun.* 2019 Mar;87(5):e00118-19.

39. Baba T, Balla T. Emerging roles of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate as regulators of multiple steps in autophagy. *J Biochem.* 2020 Oct 1;168(4):329–36.
40. Claude-Taupin A, Morel E. Phosphoinositides: Functions in autophagy-related stress responses. *Biochim Biophys Acta Mol Cell Biol Lipids.* 2021 Jun;1866(6):158903.
41. Starr T, Child R, Wehrly TD, Hansen B, Hwang S, López-Otin C, et al. Selective subversion of autophagy complexes facilitates completion of the *Brucella* intracellular cycle. *Cell Host Microbe.* 2012 Jan 19;11(1):33–45.
42. Skendros P, Mitroulis I. Host cell autophagy in immune response to zoonotic infections. *Clin Dev Immunol.* 2012;2012:910525.
43. Skendros P, Mitroulis I, Ritis K. Autophagy in Neutrophils: From Granulopoiesis to Neutrophil Extracellular Traps. *Front Cell Dev Biol.* 2018;6:109.
44. Sasaki M, Kumazaki T, Takano H, Nishiyama M, Mitsui Y. Senescent cells are resistant to death despite low Bcl-2 level. *Mech Ageing Dev.* 2001 Oct;122(15):1695–706.
45. Gomes MTR, Guimarães ES, Marinho FV, Macedo I, Aguiar ERGR, Barber GN, et al. STING regulates metabolic reprogramming in macrophages via HIF-1 α during *Brucella* infection. *PLoS Pathog.* 2021 May;17(5):e1009597.
46. Skendros P, Chrysanthopoulou A, Rousset F, Kambas K, Arampatzoglou A, Mitsios A, et al. Regulated in development and DNA damage responses 1 (REDD1) links stress with IL-1 β -mediated familial Mediterranean fever attack through autophagy-driven neutrophil extracellular traps. *J Allergy Clin Immunol.* 2017 Nov;140(5):1378-1387.e13.
47. Giambartolomei GH, Delpino MV, Cahanovich ME, Wallach JC, Baldi PC, Velikovsky CA, et al. Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to *Brucella* cytoplasmic proteins in chronic human brucellosis. *J Infect Dis.* 2002 Jul 15;186(2):252–9.
48. Rafiei A, Ardestani SK, Kariminia A, Keyhani A, Mohraz M, Amirkhani A. Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. *J Infect.* 2006 Nov;53(5):315–24.
49. Skendros P, Boura P, Chrisagis D, Raptopoulou-Gigi M. Diminished percentage of CD4+ T-lymphocytes expressing interleukine-2 receptor alpha in chronic brucellosis. *J Infect.* 2007 Feb;54(2):192–7.
50. Skendros P, Sarantopoulos A, Tselios K, Boura P. Chronic brucellosis patients retain low frequency of CD4+ T-lymphocytes expressing CD25 and CD28 after *Escherichia coli* LPS stimulation of PHA-cultured PBMCs. *Clin Dev Immunol.* 2008;2008:327346.

51. Godfroid J, Cloeckaert A, Liautard J-P, Kohler S, Fretin D, Walravens K, et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res. 2005 Jun;36(3):313–26.

417 **Table 1. Characteristics of patients with acute brucellosis (AB).**

Patient#	Sex	Age (decade)	Symptoms/ Findings	Route of transmission	Wright SAT	Blood culture	Antibiotic treatment
AB1	F	4th	Fatigue, malaise myalgias, arthralgias	Consumption	1/640	N/A	Rifampicin Doxycycline
AB2	F	6th	Fever, sweating, arthralgias, peripheral arthritis	Consumption	1/320	Negative	Rifampicin Doxycycline Amikacin
AB3	M	4th	Fever, sweating, fatigue	Consumption, contact	1/320	Negative	Rifampicin Doxycycline Amikacin
AB4	M	4th	Fever, sweating, malaise, fatigue	Consumption	1/5120	Negative	Rifampicin Doxycycline Amikacin
AB5	M	6th	Fever, sweating, lumbar spondylitis	Contact	1/160	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB6	M	7th	Fever, myalgia	Contact	1/320	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB7	M	7th	Sweating, fatigue, low back pain	Consumption	1/320	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB8	F	5th	Fatigue, lumbar spondylitis	Consumption	1/640	N/A	Rifampicin Doxycycline Amikacin
AB9	M	6th	Fever, sweating, malaise, fatigue myalgias, arthralgias	Consumption, contact	1/160	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB10	M	6th	Fatigue, myalgias, arthralgias, peripheral arthritis	Contact/REV1 vaccine	1/160	Negative	Rifampicin Doxycycline
Age (years, mean±SD)		50.0±11.6					

418

419 F; female, M; male, N/A; not available, SAT; serum agglutination test, SD; standard deviation

420 Duration of antibiotic treatment was 8-12 weeks for rifampicin (600 mg/daily) and

421 doxycycline (200 mg/daily), and 2-3 weeks for Amikacin (1 gr/daily).

422 **Figure legends**

423 **Figure 1. Alterations in the transcriptomic profile of human Mφ infected *in vitro***

424 **with *B. melitensis*.** (A) Principal component analysis (PCA) of the transcriptome of

425 all 12 Mφ samples. T1-T4 represent untreated control Mφ, T11-T14 represent samples

426 from Mφ at 2h post infection and T21-T24 represent samples at the 24h time point.

427 (B) Pathway analysis of the DEGs at 2h post-infection compared to control, using the

428 KEGG database as reference. Light blue color represents statistical significance (C)

429 Heatmaps depicting the DEGs of the respective pathways. (D) Pathway analysis of

430 the DEGs with the highest variance at 24h post infection compared to control, using

431 the KEGG database as reference. (E) Enriched biological processes in which the

432 downregulated genes are involved. (F) Heatmaps depicting the DEGs of the

433 phagosome pathway, the inflammatory response and positive regulation of IL-1β

434 production biological processes.

435 **Figure 2. Alterations in the transcriptomic profile of human PMNs infected in**

436 **vitro with *B. melitensis*.** (A) Pathway analysis of the DEGs from PMNs at 0.5h post

437 infection with *B. melitensis* compared to control, using the KEGG database as

438 reference. (B) Heatmap depicting the DEGs of the ribosome pathway. (C) Heatmap

439 depicting the DEGs of the pathways enriched for downregulated genes.

440 **Figure 3. Transcriptomic analysis of PMNs from patients with brucellosis before**

441 **treatment initiation and after successful completion of treatment.** (A) Pathway

442 analysis of the DEGs from PMNs after treatment compared to PMNs isolated from

443 the same patients (paired-data analysis) during active brucellosis, using the KEGG

444 database as reference. Light blue color represents statistical significance (B)

445 Heatmaps depicting the DEGs of the respective pathways. P1-P8 refers to different

446 patients. (C) GSEA for genes related to response to interferons, and inflammation.

447 **Figure 4. Transcriptomic analysis of PBMCs from patients with brucellosis**
 448 **before treatment initiation and after successful completion of treatment. (A)**
 449 Heatmap depicting the DEGs from PBMCs from patients with acute brucellosis
 450 before treatment initiation and from the same patients (paired analysis) after
 451 successful treatment. P1-P6 refers to different patients. (B) GSEA for genes related to
 452 response to interferons, oxidative phosphorylation and hypoxia. (C) Venn diagram and
 453 (D) heatmap depicting the common genes that were significantly differentially
 454 expressed in PMNs and PBMCs from patients with brucellosis after treatment.

455 **Figure 5. Levels of cytokines in the serum of patients with active brucellosis. (A-**
 456 **H) Levels of IFN- α , IFN- γ , IL-1 β , IL-18, TNF, IL-6, MCP-1 and IL-17A in the serum**
 457 **of patients with acute brucellosis before treatment initiation and after successful**
 458 **treatment. (I) Levels of IFN- γ in patients with chronic relapsing brucellosis during**
 459 **relapse and remission. *p<0.05, **p<0.01. Wilcoxon signed rank test.**

Figure 2

Figure 3

A

KEGG_up after treatment

KEGG_down after treatment

B

RNA transport

Autophagy

NOD-like receptor signaling pathway

Cytokine-cytokine receptor interaction

before
after

C

HALLMARK_INTERFERON_GAMMA_RESPONSE

HALLMARK_INTERFERON_ALPHA_RESPONSE

HALLMARK_INFLAMMATORY_RESPONSE

Figure 4

A

before
after

B

C

D